{
  "extraction_metadata": {
    "timestamp": "2025-10-01T15:17:30.362827",
    "source_type": "hta_submission",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "total_countries": 8,
    "temperature": 0.3
  },
  "outcomes_by_country": {
    "DE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DE",
      "Outcomes": "progression-free survival (blinded independent central review), overall survival, symptomatology (EORTC QLQ-C30), health status (EORTC QLQ-C30), symptomatology (EORTC QLQ-LC13), health status (EORTC QLQ-LC13), symptomatology (BPI-SF), health status (BPI-SF), symptomatology (FACT-G GP5), health status (FACT-G GP5), symptomatology (PGI-C), health status (PGI-C), health status (EQ-5D VAS), adverse events (general)",
      "ChunksUsed": 25,
      "ContextTokens": 4757
    },
    "DK": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DK",
      "Outcomes": "overall survival (OS), progression-free survival (PFS), progression-free survival (RECIST v1.1), investigator-assessed progression-free survival, centrally-assessed progression-free survival, objective response rate (ORR), duration of response (DoR), time to progression (TTP), time to next treatment (TTNT), event-free survival, progression after next line of therapy (PFS2), treatment discontinuation due to adverse events, adverse events (grade ≥3; CTCAE v5.0), EORTC QLQ-C30, EORTC QLQ-LC13, EQ-5D-5L, NSCLC Symptom Assessment Questionnaire (NSCLC SAQ), Patient Global Impression of Change (PGIC), Patient Global Impression of Severity (PGIS), health-related quality of life (HRQoL), quality-adjusted life years (QALYs), cost-effectiveness (incremental cost-effectiveness ratio, ICER)",
      "ChunksUsed": 25,
      "ContextTokens": 5434
    },
    "EN": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "EN",
      "Outcomes": "overall survival, progression-free survival, health-related quality of life, objective response rate (RECIST 1.1, blinded independent central review), complete response (RECIST 1.1, blinded independent central review), partial response (RECIST 1.1, blinded independent central review), adverse events, utility decrement per cycle of treatment, visual analogue scale (progression-free health state), health-state utilities, treatment-related disutility for intravenous administration",
      "ChunksUsed": 25,
      "ContextTokens": 4159
    },
    "FR": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "FR",
      "Outcomes": "objective response rate (independent review panel), progression-free survival (independent, blinded review panel; RECIST 1.1), duration of response (RECIST 1.1), disease control rate, time to response, overall survival, adverse events (general), serious adverse events (grade ≥3), EORTC QLQ-C30, EORTC QLQ-LC13",
      "ChunksUsed": 25,
      "ContextTokens": 4469
    },
    "IT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "IT",
      "Outcomes": "",
      "ChunksUsed": 10,
      "ContextTokens": 1685
    },
    "PO": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "PO",
      "Outcomes": "progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), overall survival (OS), serious adverse events (SAEs), adverse events (general), diarrhoea, increased alanine aminotransferase activity, increased asparaginase aminotransferase activity, increased AST, anaemia, headache, cough, shortness of breath, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, weight loss, oral cavity blockage, asthenia, neutropenia, peripheral neuropathy, EORTC QLQ-C30, EORTC QLQ-LC13, quality-adjusted life years (QALYs), cost-utility analysis, incremental cost-utility ratio (ICUR), years of life gained (LYG)",
      "ChunksUsed": 25,
      "ContextTokens": 5242
    },
    "PT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "PT",
      "Outcomes": "overall survival (OS), progression-free survival (PFS; RECIST v1.1), eventless survival, time to progression, time to next treatment, objective response rate (ORR), response rates, rate of disease control, duration of response (DoR), duration of treatment, dropout rate, mortality-related toxicity, adverse events (CTCAE v5.0), quality of life, significant adverse event rate (grade 3-4), adverse event rate, tolerability, susceptibility",
      "ChunksUsed": 25,
      "ContextTokens": 4549
    },
    "SE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "SE",
      "Outcomes": "progression-free survival (PFS), overall survival (OS), quality-adjusted life years (QALYs), cost-effectiveness (cost per QALY), health-related quality of life (measured by time to death)",
      "ChunksUsed": 25,
      "ContextTokens": 3929
    }
  }
}